Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 women in Brazil



      To assess the contraceptive performance of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena; Bayer Oy, Turku, Finland) among women who maintain the same device without changes after 60 months.

      Study design

      This is a chart review study in which we assessed the charts of 766 women who continue the same LNG-IUS for contraception beyond 60 months. The women were evaluated at the Family Planning clinic, University of Campinas Medical School, Campinas, SP, Brazil, from November 1990 to March 2011. We obtained sociodemographic data, duration of use, continuation and discontinuation rates and reasons, bleeding pattern at the recorded last visit. The statistical analysis was performed using Kaplan–Meier analysis.


      A total of 776 charts were identified of women who used the LNG-IUS beyond 60 months. The mean age (±S.E.M.) at LNG-IUS placement was 32.0±0.2 years (ranged 15 to 44 years; median was 32 years). The distribution of number of pregnancies was 0–1 (45%); 2–4 (54.1%) and≥5 (0.9%). The median length of the LNG-IUS' use was 73 months after placement (ranged 61–184 months). Zero pregnancies were reported and the main reasons for discontinuation were expiration of approved effective lifespan, menopause and planning pregnancy. The cumulative women-years (W-Y) of exposure were 967 and 1403 up to seven and 15 years, respectively. The main bleeding pattern reported by the women was amenorrhea.


      The 52-mg 20 μg/day LNG-IUD (Mirena) showed continue contraceptive efficacy beyond 5 years of use with no pregnancies detected over 967 and 1403 W-Y up to seven and 15 years after placement.

      Implications statement

      The 52-mg 20 μg/day LNG-IUD presented a very high contraceptive efficacy beyond the first 5 years of lifetime labeled. Increasing data support that efficacy beyond 5 years of use, and new data suggested efficacy as long as 15 years. Healthcare professionals, policy makers and stakeholders could take advantage of the present information to decide to maintain the same device at least up to seven years. Furthermore, amenorrhea could be a good indicator of contraceptive effect.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Winner B.
        • Peipert J.F.
        • Zhao Q.
        • Buckel C.
        • Madden T.
        • Allsworth J.E.
        • et al.
        Effectiveness of long-acting reversible contraception.
        N Engl J Med. 2012; 366: 1998-2007
        • Bahamondes L.
        • Bottura B.F.
        • Bahamondes M.V.
        • Gonçalves M.P.
        • Correia V.M.
        • Espejo-Arce X.
        • et al.
        Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
        Hum Reprod. 2014; 29: 2163-2170
        • Ferreira J.M.
        • Monteiro I.
        • Fernandes A.
        • Bahamondes M.V.
        • Pitoli A.
        • Bahamondes L.
        Estimated disability-adjusted life years averted by free-of-charge provision of the levonorgestrel-releasing intrauterine system over a 9-year period in Brazil.
        J Fam Plann Reprod Health Care. 2017; 43: 181-185
        • United Nations, Department of Economic and Social Affairs, Population Division
        Trends in Contraceptive Use Worldwide 2015 (ST/ESA/SER.A/349).
        (Available at:)
        • Hidalgo M.M.
        • Hidalgo-Regina C.
        • Bahamondes M.V.
        • Monteiro I.
        • Petta C.A.
        • Bahamondes L.
        Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
        Contraception. 2009; 80: 84-89
        • McNicholas C.
        • Maddipati R.
        • Zhao Q.
        • Swor E.
        • Peipert J.F.
        Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the US Food and Drug Administration approved duration.
        Obstet Gynecol. 2015; 125: 599-604
        • Wu J.P.
        • Pickle S.
        Extended use of the intrauterine device: a literature review and recommendations for clinical practice.
        Contraception. 2014; 89: 495-503
        • Rowe P.
        • Farley T.
        • Peregoudov A.
        • Piaggio G.
        • Boccard S.
        • Landoulsi S.
        • et al.
        Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A.
        Contraception. 2016; 93: 498-506
        • Sivin I.
        • Stern J.
        Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR).
        Fertil Steril. 1994; 61: 70-77
      1. SAS Institute The SAS System for Windows.
        in: Release 9.3 Cary. SAS Inst, NC, USA2011
        • R Development Core Team R
        A Language and Environment for Statistical Computing.
        R Foundation for Statistical Computing, Vienna, Austria2012 ([ISBN 3-900051-07-0; Available at: http://wwwR-projectorg/ Accessed June 1, 2017])
        • ESHRE Capri Workshop Group
        Intrauterine devices and intrauterine systems.
        Hum Reprod Update. 2008; 14: 197-208
        • Nilson C.G.
        • Lahteenmaki P.
        • Luukkainen T.
        • Robertson D.N.
        Sustained intrauterine release of levonorgestrel over five years.
        Fertil Steril. 1986; 45: 805-807
        • Ronnerdag M.
        • Odlind V.
        Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use.
        Acta Obstet Gynecol Scand. 1999; 78: 716-721
        • Schwartz D.
        • Mayaux M.J.
        Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands.
        Federation CECOS N Engl J Med. 1982; 306: 404-406
        • Seeber B.
        • Ziehr S.C.
        • Gschliesser A.
        • Moser C.
        • Mattle V.
        • Seger C.
        • et al.
        Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system.
        Contraception. 2012; 86: 345-349
        • Creinin M.D.
        Comments on: “Extended use of the intrauterine device: a literature review and recommendations for clinical practice”.
        Contraception. 2014; 90: 104
        • Díaz J.
        • Díaz M.M.
        • Pastene L.
        • Araki R.
        • Faúndes A.
        Randomized clinical study of the T-Cu 380A and the Lippes loop C, in Campinas, Brazil.
        Contraception. 1982; 26: 221-228
        • Hidalgo M.
        • Bahamondes L.
        • Perrotti M.
        • Diaz J.
        • Dantas-Monteiro C.
        • Petta C.
        Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years.
        Contraception. 2002; 65: 129-132
        • Díaz J.
        • Bahamondes L.
        • Díaz M.
        • Marchi N.
        • Faúndes A.
        • Marini M.
        Evaluation of the performance of the copper T380A IUD up to ten years. Is this IUD a reversible but potentially permanent method?.
        Adv Contracept. 1992; 8: 275-280
        • Eisenberg D.L.
        • Schreiber C.A.
        • Turok D.K.
        • Teal S.B.
        • Westhoff C.L.
        • Mitchell D.
        Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.
        Contraception. 2015; 92: 10-16